In which Alex Zhavoronkov, founder and CEO of Insilico Medicine, discusses how AI can accelerate drug R&D, from target identification to clinical trials. He also shares his own path from computer science to biotech, explains how Insilico’s business model has evolved, and gives advice on leading interdisciplinary teams.

In which Adam Feuerstein, national biotech columnist at the healthcare and life science digital media company STATNews, discusses his experience covering the biotech sector from a business-focused perspective. He also shares his views on past and future trends of the industry from technological, financial, and regulatory lenses.

In which Sean Escola (MD, PhD), a theoretical neuroscientist and psychiatrist at Columbia University, discusses his research background and gives insights into neuro-inspired AI. He also shares his experiences with founding a drug discovery company: Herophilus, Inc. and a non-profit: Neuromatch Academy.

In which Caleb Bates discusses his work in life sciences patent prosecution and strategic patent portfolio management at Fish & Richardson. Caleb also discusses technology transfer as well as trends in life science patent portfolios. 

In which David Sable, a portfolio manager for the Special Situations Life Sciences Fund and a lecturer in the Biology Department at Columbia University, shares insights about life science investing. David also discusses the need for investing in reproductive medicine, specifically in vitro fertilization.

In which Samuel Sia, a co-founder of Harlem Biospace, shares insights about successful life sciences startups. Sam also discusses his past experience with founding his own biotech startups as well as his goals as the newly appointed Vice Provost for the Fourth Purpose and Strategic Impact at Columbia University.

In which Kris Ramadurai, a partner at Harmonix Fund, shares insights about life sciences venture capital. Kris describes the process of investing in early stage biotech startups and the differences between tech VC and life sciences VC.

In which Zack Abbott, PhD, discusses his company ZBiotics. ZBiotics is a biotechnology startup that is focused on engineering microorganisms for consumer benefit. Zack talks about the company's current product, a genetically engineered probiotic designed to breakdown acetaldehyde, a toxic byproduct of alcohol. Additionally, Zack offers insight on his transition from completing a PhD to the biotech start-up space. 

Hello and welcome to Columbia University BioWorks! This is a podcast focused on life science business, entrepreneurship, policy, and investment. Listen in to hear conversations with a diverse array of guests making "bio work" in the real world.

If you’re interested in academic research, be sure to check out our sister podcast - Columbia University Bio Bytes - at this link: https://anchor.fm/biobytes

Hope to see you soon!